Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IV immunoglobulin does not reverse established weakness in MS.

J H Noseworthy1, P C O'Brien, B G Weinshenker

  • 1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. noseworthy.john@mayo.edu

Neurology
|November 9, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generative Adversarial Networks for Brain MRI Synthesis: Impact of Training Set Size on Clinical Application.

Journal of imaging informatics in medicine·2024
Same author

Accurate core temperature measurement during Caesarean delivery. Comment on Br J Anaesth 2021; 126: 500-15.

British journal of anaesthesia·2021
Same author

Resistant fabric warming is a viable alternative to forced-air warming to prevent inadvertent perioperative hypothermia during hemiarthroplasty in the elderly.

The Journal of hospital infection·2021
Same author

Treatment of MOG antibody associated disorders: results of an international survey.

Journal of neurology·2020
Same author

Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity.

Experimental neurology·2020
Same author

Reducing Implant Infection in Orthopaedics (RIIiO): Results of a pilot study comparing the influence of forced air and resistive fabric warming technologies on postoperative infections following orthopaedic implant surgery.

The Journal of hospital infection·2019
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Intravenous immunoglobulin (IVIg) did not improve established muscle weakness in multiple sclerosis (MS) patients. This randomized trial found no significant benefit in muscle strength or disease activity over six months.

Area of Science:

  • Neuroscience
  • Immunology
  • Clinical Trials

Background:

  • Immunoglobulin (Ig) administration has shown potential for remyelination in animal models of multiple sclerosis (MS).
  • Persistent muscle weakness is a common and debilitating symptom in MS patients.

Purpose of the Study:

  • To evaluate the efficacy of intravenous immunoglobulin (IVIg) in improving established muscle weakness in patients with multiple sclerosis (MS).
  • To assess the impact of IVIg on muscle strength, relapse behavior, and overall impairment in MS.

Main Methods:

  • A randomized, double-blinded, placebo-controlled trial involving patients with stable, persistent muscle weakness in MS.
  • Participants received either IVIg or placebo over a 3-month period, with isometric muscle strength as the primary outcome measure.

Related Experiment Videos

  • Targeted neurologic deficit (TND) muscle groups were specifically monitored for therapeutic response.

    • Main Results:

    • IVIg was well-tolerated but showed no significant difference in improving muscle strength compared to placebo at 6 months.
    • No apparent benefit was observed in relapse behavior or impairment measures in either treatment group.
    • Patients with active MS during the trial experienced worsening of weakness, irrespective of IVIg treatment.

    Conclusions:

    • Intravenous immunoglobulin (IVIg) is not effective in reversing established muscle weakness in multiple sclerosis (MS).
    • Isometric muscle strength measurements are reliable and sensitive tools for assessing functional changes in future MS clinical trials.